Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
News
Roche's Astegolimab Shows Mixed Results in COPD Trials, Phase IIb Study Meets Primary Endpoint
Roche's pivotal Phase IIb ALIENTO study met its primary endpoint, showing astegolimab reduced annualized exacerbation rate by 15.4% in COPD patients at 52 weeks.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
WHO Includes ArkBio's Ziresovir in Pediatric RSV Drug Priority List, Marking First Chinese Anti-RSV Drug Recognition
The World Health Organization has included ziresovir (10mg) from Shanghai Ark Biopharmaceutical in its PADO-RSV priority list, making it the first and only RSV antiviral drug selected for the program.
Xaira Therapeutics Appoints Jeff Jonker as President and COO to Scale AI-Driven Drug Discovery Platform
Xaira Therapeutics has appointed biotech veteran Jeff Jonker as President and Chief Operating Officer to help scale its AI-enabled drug discovery platform and drive the next phase of growth.
FDA Approves First Xolair Biosimilar Omlyclo for Allergic Diseases, Marking Milestone in Allergy Treatment Access
The FDA has approved Omlyclo (omalizumab-igec) as the first biosimilar interchangeable with Xolair for treating allergic asthma, chronic rhinosinusitis with nasal polyps, chronic urticaria, and food allergies.
Novel Tiancimycin-Based Antibody-Drug Conjugate Shows Promise Against Aggressive Lymphoma
Scientists at The Herbert Wertheim UF Scripps Institute developed a novel antibody-drug conjugate combining tiancimycin, a natural compound from soil microbes, with a "double-decker" antibody targeting CD79b for diffuse large B cell lymphoma treatment.
Roche Announces Leadership Changes as Head of Pharma R&D Hans Clevers Retires
Johannes (Hans) Clevers, Head of Roche Pharma Research and Early Development (pRED), will retire at the end of August 2025 after accelerating several potentially transformational medicines into final development phases.
NCT/UCC Dresden Launches Phase 2 Trial of Personalized mRNA Vaccine for Pancreatic Cancer
NCT/UCC Dresden becomes the only site in Saxony to offer patients access to BioNTech and Genentech's personalized mRNA vaccine Autogene Cevumeran for pancreatic cancer treatment.
Isomorphic Labs Appoints Dr. Ben Wolf as Chief Medical Officer, Establishes US Operations
Isomorphic Labs, the AI-first drug discovery company, has appointed Dr. Ben Wolf as Chief Medical Officer to lead translation of AI-driven discoveries into clinical medicines.
AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint
AbbVie's Phase 3 VERONA trial evaluating venetoclax plus azacitidine in newly diagnosed higher-risk myelodysplastic syndrome failed to meet its primary endpoint of overall survival with a hazard ratio of 0.908 and p-value of 0.3772.